story of the week
Ublituximab vs Teriflunomide for Relapsing MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
N. Engl. J. Med 2022 Aug 25;387(8)704-714, L Steinman, E Fox, HP Hartung, E Alvarez, P Qian, S Wray, D Robertson, D Huang, K Selmaj, D Wynn, G Cutter, K Mok, Y Hsu, Y Xu, MS Weiss, JA Bosco, SA Power, L Lee, HP Miskin, BAC CreeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.